A detailed history of Exchange Traded Concepts, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Exchange Traded Concepts, LLC holds 2,031 shares of BPMC stock, worth $196,235. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,031
Previous 2,536 19.91%
Holding current value
$196,235
Previous $273,000 31.5%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$84.1 - $120.5 $42,470 - $60,852
-505 Reduced 19.91%
2,031 $187,000
Q2 2024

Aug 13, 2024

SELL
$85.18 - $108.78 $63,799 - $81,476
-749 Reduced 22.8%
2,536 $273,000
Q1 2024

Apr 15, 2024

BUY
$73.17 - $99.79 $37,682 - $51,391
515 Added 18.59%
3,285 $311,000
Q4 2023

Jan 05, 2024

BUY
$43.96 - $92.84 $30,903 - $65,266
703 Added 34.01%
2,770 $255,000
Q3 2023

Oct 18, 2023

SELL
$46.9 - $66.0 $17,399 - $24,486
-371 Reduced 15.22%
2,067 $103,000
Q2 2023

Jul 20, 2023

BUY
$42.2 - $66.37 $102,883 - $161,810
2,438 New
2,438 $154,000
Q2 2022

Jul 20, 2022

BUY
$45.23 - $70.15 $422,810 - $655,762
9,348 New
9,348 $472,000
Q1 2022

Apr 26, 2022

SELL
$54.1 - $110.08 $35,760 - $72,762
-661 Closed
0 $0
Q4 2021

Jan 13, 2022

BUY
$94.25 - $115.99 $21,206 - $26,097
225 Added 51.61%
661 $71,000
Q3 2021

Oct 18, 2021

BUY
$80.98 - $109.47 $9,798 - $13,245
121 Added 38.41%
436 $45,000
Q2 2021

Jul 30, 2021

BUY
$82.78 - $101.0 $26,075 - $31,815
315 New
315 $28,000
Q1 2021

Apr 20, 2021

SELL
$90.71 - $108.28 $545,711 - $651,412
-6,016 Closed
0 $0
Q4 2020

Jan 19, 2021

SELL
$92.08 - $124.48 $223,570 - $302,237
-2,428 Reduced 28.75%
6,016 $675,000
Q3 2020

Oct 30, 2020

BUY
$66.45 - $92.7 $561,103 - $782,758
8,444 New
8,444 $783,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.77B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Exchange Traded Concepts, LLC Portfolio

Follow Exchange Traded Concepts, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exchange Traded Concepts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exchange Traded Concepts, LLC with notifications on news.